Oral Gallium Maltolate for Recurring Brain Tumors
Part of Cancer clinical trials.
This early-stage trial tests whether a new oral medication called gallium maltolate can help slow or shrink glioblastoma (a serious brain tumor) that has come back after initial treatment. The study enrolls patients who have already had standard brain tumor treatment and whose tumors are growing again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can provide informed consent
- You have been diagnosed with glioblastoma (a grade IV brain tumor) confirmed by tissue sample or imaging
- You completed standard brain tumor treatment (radiation and chemotherapy with temozolomide) and finished chemotherapy at least 4 weeks ago
- Your tumor has grown back on imaging and a team of brain cancer specialists agrees you need another surgery
- You are neurologically stable with no new or worsening brain-related symptoms for at least 14 days
- Your blood counts and liver/kidney function are adequate to safely receive the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.